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Abstract
Two ternary copper(ll) complexes of indomethacin [1-(4-chlorobenzoyl)-5-methoxy-2-
methyl-l-H-indole-3-acetic acid] called hereafter Indo, were prepared and characterized by single
crystal X-ray diffraction. The first complex Cou2(Indo)4(DMF) crystallizes in space group P-1 (a
10.829(2), b 13.379(2), c 16.491(3) A; (z 105.58(2), I 101.06(2), y 106.96(2); V=
2104.6(6) ,&,3, Z= 1). The title molecule is a centrosymmetric binuclear complex, with Cu atoms
bridged by the carboxylate moieties of four indomethacinate ligands. The four nearest O atoms
around each Cu atom form a square planar arrangement with the square pyramidal coordination
completed by the O atom of N,N’-dimethylformamide. Daily administration for seven days of mg/kg
of indomethacin, land encapsulated into liposomes induces a weak inflammation of rat gastro-
intestinal tract. was less inflammatory than indomethacin but the better protection was brought by
encapsulation of the compound. This might be of interest in sustained therapies of chronic
inflammatory diseases.
1. Introduction
Alzheimer’s disease (AD), the third most costly disease after cancer and heart diseases [1], is
a neurodegenerative disorder, the primary or neuropathogenic mechanism of which is unknown.
This disease is characterized by abnormal accumulation of amyloid peptide (1 A4) from its precursor
amyloid precursor protein. Mutations in the gene encoding amyloid precursor on chromosome 21
have been found to segregate with AD [2]. The inflammatory hypothesis of Alzheimer’ s disease is
based on the observation that individuals susceptible to the disease and who are undergoing
treatment for a known inflammatory injury will be inadvertently treating their latent AD and will
therefore have a reduced risk of developing a clinical case [3-4]. It was hypothesized that
antiinflammatory drugs such as NSAIDs may slow the onset or progression of AD by reducing
inflammation in brain due to the deposition of amyloid protein and consequent damage to brain
cells. Activated microglia are found to be present in AD [5] and associated with the generation of
components of the classical complement pathway, demonstrating the onset of an inflammatory
process. Moreover, some of these components stimulate the respiratory burst system of the
microglia, resulting in the production of toxic reactive oxygen species such as superoxide anion,
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hydrogen peroxide and hydroxyl radical [5]. Current clues to possible treatment include the
potential use of antioxidants, oestrogens, antiinflammatory drugs or compounds altering amyloid
metabolism. Strategy in addressing the stimulation of the immune system has been effective in
reducing AD progression in clinical trials related to the cyclooxygenase inhibitor indomethacin [6],
which rapidly and efficiently penetrates the blood-brain barrier. While aspirin [7], ibuprofen [8] and
indomethacin [9] are at best only very weak free radical scavengers in vitro systems, their copper
complexes are very efficient free radical scavengers [10]; these drugs are thus expected to
circumvent the toxicity of reactive oxygen species generated in the activated microglia.
Even if NSAIDs prove to confer a protective benefit against inflammatory brain disorders, their use is
often associated with a broad spectrum of untoward reactions, particularly in the gastrointestinal
tract which may constitute a limiting factor for their continuous administration [11]. Copper(ll)
complexes of NSAIDs may constitute an alternative way. These complexes are extensively studied
since Sorenson demonstrated that they are more active than their parent drugs and exhibit
antiulcer activity [12,13]. Further, a recent investigation of copper(ll) complex equilibria (under
physiological conditions) with salicylic or acetylsalicylic acids has shown that their anions may favour
the gastrointestinal absorption of copper(ll) [14]. In previous work, Sorenson described the
synthesis of many copper(ll)-NSAIDs complexes and among them, Cu-indomethacin complex
[12,13].
In 1980, Weser et al. reported the crystal structures of Cu2(indomethacin)4.L2 (L=H20, DMSO), the
latter complex of which was also solvated by DMSO molecules and with an R(F) factor 0.13 in the
final refinement [15]. Thus, a more acurate refinement seemed desirable. This paper presents the
synthesis of new ternary complexes Cu2(Indo)4(DMF)2 and [Cu2(Indo)4(DMF)2].2DMF II and the
molecular and crystal structure of I.
Moreover, we have previously demonstrated intestinal damage induced by a high dose of
indomethacin [16]. In this study, we investigated the effect produced on rat intestine by daily
administration of Cu2(Indo)4(DMF)2, relative to indomethacin at the commonly prescribed dose of
mg/kg. It has been speculated that endogenous nitric oxide (NO) mediates inflammatory processes
[17-19]. Nitrite production by intestinal tissues from treated animals has thus been measured in
parallel to nitric oxide synthase (NOS) activities. Intensity of the inflammatory reaction was evaluated
by measurement of myeloperoxidase activity in the same tissues.
2. Results
2.1 Description of the structure.
The bond distances and angles in copper coordination spheres are listed in table 1. The
molecular conformation of Cu2(Indo)4(DMF)2 is illustrated in Figure 1. As the DMF ligand is
disordered, only one of its two components is shown.
Copper environment
The complex Cu2(Indo)4(DMF)2 is dimeric and exhibits a symmetry center:two Cu atoms
are surrounded by two crystallographically independent indomethacinate groups, one DMF ligandl
on one side, and by their centrosymmetric counterparts, on the other side. The DMF ligands are
coordinated to Cu atoms through the O atom.
The indomethacinate groups are bidentate and act as syn-syn bridging ligands between the
isolated pairs of copper atoms separated by Cu...Cu 2.629(2)A (symmetry code i: -x, y, z) in
compound I. These distances do not differ significantly from the 2.632(6) ,/k value observed for
Cu2(Indo)4.L2 (L H20 or DMSO) which might be solvated by DMSO molecules III [15]. However,
these distances are longer than the bond length 2.55 ,&, in metallic copper [20]. Nevertheless, they
lie within the range 2.610 2.688(1) A found in dimeric copper (11) benzoates and are also close to
those found in copper-NSAIDs complexes 2.6265(8) ,/k in Cu2(diclofenac)4(DMF)2, and 2.629(1)
in Cu2(naproxen)4(DMSO)2 [21-23]. The four nearest O atoms around each Cu atom form a square
planar arrangement with the copper to carboxylato bond distances in the range from 1.956(7) to
1.967(7) ,/k in I. The square pyramidal environment is completed by the O atom from N,N’-
dimethylformamide, at a distance of 2.154(6) A in I. Similar Cu O(DMSO) or Cu O(DMF) apical
bond lengths are observed for previously reported Cu-NSAID complexes :in the range from
2.123(5) to 2.16(2) ,&, [15, 22-23]. The Cu atom in lies 0.202(3) ,&, out of the O atoms least-squares
plane towards the DMF oxygen atom. It is well known that the axial ligand plays a role in determining
both the Cu Cu and Cu O basal plane distances. The O(100) Cu Cu angle is 177.2(2) and the
dihedral angle between the plane through Cu- O(1)- C(1)- 0(2)- Cu and Cu- O(21)- C(21) 0(22)
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Cu is 89.9(2) in I. In conclusion, the crystal structures of is essentially the same as in III except for
the DMF or DMSO accomodation. However, compare to the molecular structure of the
indomethacin free ligand [24], there is a conformation change in the second indomethacinate
ligand as shown by the 0(3) C(13) N(1) C(10) and O(23)-C(33)-N(21)-C(30) torsion values in
compound I.
Torsion angles (o)
O(3)-C(13)-N (1)-C(10)
O(23)-C(33)-N(21 )-C(30)
[Cu2(Indo)4(DMF)2]
24.8
149,0
Indomethacin free ligand
-25.5
NIO0
022 C23 C33
C6
C24
C25
C16 C26
C17
C18
03
Figure Perspective view of Cu2(Indo)4(DMF)2 generated by CAMERON using 20% probability
ellipsofds for the non-hydrogen atoms. The cstallographic labelling is shown. Hydrogen atoms are
omitted for clarity.
2.2.Biological properties
2.2.1. Intestinal damage score.
Daily administration for seven days of mg/kg of indomethacin and Cu2(Indo)4(DMF)2
compound encapsulated or not, did not induce gastric or intestinal damages.
2.2.2. Myeloperoxidase activity in intestine tissue.
An inflammatory process has been demonstrated by a significant enhancement of MPO
activity in intestinal tissue after administration of NSAIDs (Figure 2). This enzyme released by
inflammation cells and particularly polymorphonuclear cells is generally considered as a good marker
of inflammatory process and classically measured to appreciate such a phenomenon. Since
myeloperoxidase-mimetic activity has been reported with some copper complexes [12-25], similar
enhancement of tissue myeloperoxidase content after treatment with indomethacin and copper
indomethacinate complex might be partly due to the proper effect of the complex more than to a
proinflammatory effect of this compound. Conversely, encapsulation of copper indomethacinate
counteracted this increase.
2.2.3. iNO$ activity and nitrite production in intestine tissue.
iNOS activity and nitrite production were significantly enhanced in intestine tissue after
administration of indomethacin but Cu2(Indo)4(DMF)2 did not induce as much inflammation (table 2),
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with a lesser extent when Cu2(Indo)4(DMF)2 was used. No significant effect was observed when this
compound was encapsulated.
Table 1. Coordination sphere in Cu2(Indo)4(DMF)2
Distances [A]
Cu(1)-O(22) 1.956(7)
Cu(1 )-O(2) 1.961 (7)
Cu(1)-O(21) 1.963(6)
Cu(1)-O(1) 1.967(7)
Cu(1 )-O(100) 2.154(6)
Cu(1)-Cu(1) 2.629(2)
O(22)i-Cu(1 )-O(2)
O(22)i-Cu(1 )-O(21)
O(2)i-Cu(1)-O(21)
O(22)i-Cu(1)-O(1)
O(2)i-Cu(1)-O(1)
O(21)-Cu(1)-O(1)
O(22)i-Cu(1)-O(100)
O(2)i-Cu(1 )-O(100)
O(21 )-Cu(1 )-O(100)
O(1)-Cu(1)-O(100)
O(22)i-Cu(1)-Cu(1 )i
O(2)i-Cu(1)-Cu(1 )i
O(21 )-Cu(1 )-Cu(1 )i
o()-Cu()-Cu()
o( oo)-cu()-Cu( )i
c()-o()-Cu()
c(1)-o(2)-Cu(1)
c(21)-o(21)-Cu(1)
c(21 )-o(22)-Cu(1)
C(200)-O(100)-Cu(1)
Angles [o]
89.5(3)
168.3(2)
89.5(3)
89.1(3)
168.1(3)
89.5(3)
94.0(3)
94.7(3)
97.8(3)
97.3(3)
83.9(2)
83.6(2)
84.4(2)
84.5(2)
177.2(2)
123.2(6)
123.6(6)
122.3(6)
123.5(5)
111(1)
Symmetry transformations used to generate equivalent atoms: i" -x,-y+l ,-z+l
2.2.4. Antiinflammatory activity of encapsulated copper indomethacinate.
Antiinflammatory property of copper indomethacinate was verified by the reduction of
carrageenan-induced paw edema in treated animals in comparison with solvent (RPMI + 1% DMF)-
treated rats (Figure 3).
MPO (mU/mg of proteins)
10
Control Indo Control Indu
nanocapsules
Indo-Cu
nanocapsules
Figure 2 Myeloperoxydase production in intestine tissue from animals treated by RPMI medium
(C), saline containing empty nanocapsules (C nano), indomethacin (indo), Cu2(Indo)4(DMF)2 (indo
Cu) or encapsulated Cu2(Indo)4(DMF)2 (indo-Cu nano).
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Control
Control nanocapsules
Indomethacin
Cu2(Indo)4(DM F)2]
[Cu2(Indo)4(DM F)2 nanocapsules
iNOS Nitrite
0.1 + 0.1 0.12 +0.06
0.09 + 0.09 0.09 + 0.05
1.0 + 0.3 0.31 + 0.05
0.2 + 0.1 0.27 + 0.08
0.17 + 0.09 0.22 + 0.03
Table 2 Inducible NO synthase activities and nitrite production in intestine from rats treated by
RPMI medium (control), empty nanocapsules, indomethacin, Cu2(Indo)4(DMF)2 or encapsulated
Cu2(Indo)4(DMF)2. iNOS activities are expressed in pmol/mg of proteins/hour. Nitrite is expressed
as lmol/g of tissue. Results are expressed as mean + SEM; n 6 rats per group.
Although gastrointestinal damage was not observed in our experimental protocol, an inflammatory
process was demonstrated in these tissues by enhancement of MPO and iNOS activities.
Cu2(Indo)4(DMF)2 induced a lesser inflammation especially when it was administred after
encapsulation. Prostaglandins and NO are recognized as critical mediators of gastrointestinal
defence [11, 26]. These mediators modulate mucosal blood flow, mucus release and repair of
tissue injury whereas they are able to decrease neutrophil adherence and, thus, neutrophil
activation. In our experimental series, copper indomethacinate activated less iNOS than
indomethacin, while nitrite production which is the ultimate step of a complex biological cascade,
was similarly enhanced. Copper complexes of NSAIDs have already been found more effective
than their parent drugs on animal models of inflammation and endowed of antiulcer,
anticonvulsivant and anticancer properties [12, 27].
In a previous study, we showed that high doses of copper indomethacinate exerted a slight
protective effect on the gastrointestinal tract [16]. This effect seems to be due to free radical
scavenging properties more than to a modulation of NOS activity and was strongly potentiated by
drug encapsulation. Gastrointestinal inflammation which is the worse side effect of NSAID
administration can be decreased by copper complexes and moreover by encapsulation in
liposomes or nanocapsules [16]. This might be of interest in sustained treatments of chronic
inflammatory diseases.
Edema volume
25-
20"
15
10"
-.43--- controls
Indo-Cu nano
0
0 2 4 6 8
Time (hours)
Figure 3 Time course effect of controls and encapsulated Cu2(Indo)4(DMF)2 on carrageenan-
induced paw edema. p < 0.05
3. Experimental (Materials and Methods)
3.1. Synthesis of the copper-indomethacinate complexes.
The complex Cu2(indo)4 (DMF)2 was synthesized using a modified Sorenson’s procedure
[12]. Indomethacin (Sigma, Saint-Louis, Mo, USA) (0.716 g, 2x10- mol) was dissolved in 50 ml of
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CH3OH by heating and added to 10 ml of a methanol solution containing CuCI2 (0.134 g, 10-3 mol).
Solution of NaOH (2.10-3 mol) was added slowly. After stirring (about 2 hours), the obtained
precipitate was collected by filtration, washed with methanol and diethyl ether, dried at 100C
overnight and dissolved in dimethylformamide (DMF). Slow crystallization of this solution gave
green plates of compound I. However, elongated and green crystals of compound II were obtained
using the following procedure indomethacin (2.10-3 mol.) and CuCI2 (10.3 molo) were dissolved in
DMF (50 ml). NaOH 1M solution (2.10-3 mol.) was added slowly. A green solution was obtained and
left upon standing. A slow crystallization gave compound II.
3.2. Preparation of copper-indomethacinate loaded liposomes.
Liposomes were prepared by the method of Stainmesse et al. [28]. The organic phase
consisted of lipofd S75 (200 mg), Cu2(Indo)4(DMF)2 (30mg), cholesterol (167 mg), and ethanol (25
ml). This organic phase was poured into an aqueous phase (20 ml) under moderate magnetic
stirring. Ethanol was then totally removed under reduced pressure and the suspension
concentrated to the convenient final volume under same conditions.
3.3. Structure determination
Data for compound were collected on a Stoe IPDS (Imaging Plate Diffraction System) using
MoKo radiation (X= 0.71073 A). The crystal-to-detector distance was 100 mm. 167 frames (8 min
per exposure) were obtained with 0 < q) < 250 and with the crystals oscillated through 1.5 in
Coverage of the unique set was over 95% complete to at least 20.8
Table 3. Crystal data and structure refinement
Crystal parameters
Empirical formula
Formula weight
Crystal system
Space group
Unit cell dimensions a, A
b,A
c,, &,
I y,o
Volume, A3
Z
Calculated density (g.cm-3)
Absorption coefficient (mm-)
F(00O)
Crystal size
Data collection
Diffractometer
Monochromator
Wavelength
Temperature
Theta range for data collection
Completeness to 2theta
Ranges of h, k,
Reflections collected
Independent reflections
Refinement
Refinement method
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [l>2sigma(I)]
R indices (all data)
Largest diff. peak and hole
Cu2(Indo)4(DMF)2 (I)
082 H74 CI4 Cu2 N6 O18
1700.36
Triclinic
P
10.8291(15)
13.379(2)
16.491(3)
105.58(2)
101.059(19)
106.960(17)
2104.6(6)
1.342
0.701
878
0.56 x 0.35 x 0.25 mm
IPDS Stoe
graphite
0.71073 /,
293(2) K
1.70 to 20.82 o
94.8%
-10 to 10, -13 to 13, -16 to 16
11321
4193
Full-matrix least-squares on F2
4193 / 165 / 542
1.029
R1 0.08, wR2 0.22
R1 0.12, wR2 0.24
0.87 and -0.31 e. ,&,-3
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Crystal decay was monitored by measuring 200 reflections per image. The final unit cell parameters
were obtained by the least-squares refinement of 5000 reflections. Only statistical fluctuations were
observed in the intensity monitors over the course of the data collection. Owing to the rather low #R
value, 0.24 for I, no absorption corrections were considered.
The structures were solved by direct methods (SIR92) [29] and refined by least-squares
procedures on F. For both the compounds, the DMF ligand is severely disordered. It appears on
two forms, having the O and N atoms in common. The occupancy factors for the C atoms are in the
ratio 0.54(2)/0.46(2)/in I. All these disorders were treated using a fully constrained refinement (site
occupancies, coordinates, thermal parameters) with the help of the SHELXL-97 program [30]. The
H atoms were introduced as riding model. They were given isotropic thermal parameters 20%
higher than those of the carbon to which they are attached.
Least-squares refinements were carried out by minimising the function T_.W(Fo--Fc), where Fo
and Fc are the observed and calculated structure factors. The weighting scheme used in the last
refinement cycles was w=1/[2 (Fo2)+(XP)] where P=(Fo+2Fc)/3 and X= 0.1448 for I. Details of
data collection and refinement are given in Table 3.
Calculations were performed with the SHELXL-97 programs [30] running on a PC. The
drawing of the molecule was obtained using CAMERON [31]. The fractional atomic coordinates and
the equivalent thermal parameters for all atoms but H, anisotropic thermal parameters for non
hydrogen atoms and atomic coordinates for H atoms have been deposited at the Cambridge
Crystallographic Data Centre.
3.4 Biological assays
3.4.1.Animals and treatments
Animals Male Sprague-Dawley rats (Dpr, Bourges, France) of 160 to 180 g mass were fed
standard laboratory chow (UAR Villemoisson/Orge, France) and water ad libitum.
Treatment-protocol.
Rats were daily administered by gavage at the same hour and decapitated on the 8th day.
Peritoneum was opened and 30 cm of intestine above the ileo-Cacal valve were collected. This
tissue was rinsed with phosphate-buffer saline (PBS pH 7.4), opened along the antimesenteric
border and observed to quantify possible ulcerations. One cm-length pieces were taken 10, 20 and
30 cm above the ileo-caecal valve, and pooled for tissular determination of myeloperoxidase (MPO)
and nitric oxide synthases (NOS) activities. Tissue culture ex-vivo for five hours led to collection of
supernatants in which nitrite amount was determined.
3.4.2. Intestinal damage scores.
Jejuno-ileum ulceration was round, segmental and sometimes confluent. Damage was
scored by tracing the outline of ulcerated areas from two-fold magnified photographic images onto
paper, and massing the cut-outs. Jejuno-ileum damage score (expressed in %) was expressed as
the ratio: sum of ulcerated areas/total photographed area x’100 [32].
3.4.3. NOS activities in tissue samples.
Tissue iNOS activity was estimated by measuring the conversion of L-4C-arginine to L-4C-
citrulline as described by Bush et al. [33]. Tissue samples (approximately 250 mg) were
homogenized in buffer (pH 7.4) containing 50 mM Tris-HCI, mM dithiotreitol, 23.4 #M leupeptin,
14.6 #M pepstatin and mM phenylmethylsulfonylfluoride (PMSF). After sonication on ice and
centrifugation at 250 g for 30 min at 4C, 100 1 of the supernatant were added to a reaction mixture
containing 50 mM TrisHCI (pH 7.4), 1.58 #M L-4C-arginine, 200 #M NADP, 10 #M flavin
mononucleotide, 10 #M flavine adenine dinucleotide, mM dithiotreitol, 50 IM
tetrahydrobiopterine and 50 mM valine, with 2 mM CaCI2 (total NOS activity) or mM EDTA and
mM EGTA (iNOS activity). After 10 min of incubation at 37C, the enzymatic reaction was terminated
by adding cold phosphate buffer (pH 5.5) containing 3 mM EDTA. L-14C-citrulline was separated by
applying samples to columns containing pre-equilibrated Dowex AG50W-X8, eluting them with
water and measuring the amount of radioactivity by means of scintillation counting. Protein content
was measured according to Lowry [34]. Enzyme activity is expressed as picomols of citrulline
formed per milligram of protein per hour.
3.4.4 Culture ex-vivo.
After the sacrifice of rats, intestinal tissue was carefully washed three times in sterile and
apyrogen normal saline, then cultured in a 24-well plate (Nuncleon, France) with 1.6 ml of RPMI
1640 medium (Sigma, Saint-Louis, Mo, USA) without phenol red and supplemented with penicillin
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(100 IU/ml)/streptomycin (100 #g/ml). Tissues were cultured for 5 hours in a humid atmosphere at
37iC with 5% CO2. After that time, supernatants were collected and kept at -80C before
determination of nitrite amounts.
3.4.5. Nitrite measurement in tissue culture supernatants.
Nitrite was measured as an indicator of NO formation [35]: concentration was determined in
duplicate spectrophotometrically using the Griess reagent (1% sulfanimide, 0.1%
naphthylenediamine dihydrochloride, and 2.5% H3PO4) [36]. Final concentrations were expressed
as mmole/mg of tissue.
3.4.6. MPO activity in tissue samples.
MPO activity was measured as described by Maehly and Chance [37]. MPO was extracted
from tissue by suspending the material in lysis buffer containing 20 mM KH2PO4 and 1.4 mM
hexadecyltrimethyl ammonium bromide (HTAB) (pH 6.0), before homogenization on ice with a
Polytron homogenizer. Homogenates were freezed and thawed twice, sonicated on ice 30 sec and
centrifuged. The supernatant was assayed spectrophotometrically for MPO activity: 500 #1 of
suspension was combined with 2500 #1 of buffer (pH 6.0) containing 0.16 mM Na2HPO4, 18.4 mM
KH2PO4, 44.8 #M guaicol and 0.04% hydrogen peroxide. The kinetics of absorbance at 470 nm
was recorded with a spectrophotometer thermostated at 40C. One unit of MPO activity is defined
as that degrading pmole of peroxide per minute. Change in absorbance for each sample was
expressed in international units (IU) by using a standard curve of horseradish peroxidase
established in the same experimental conditions. MPO activity is expressed as milliunits (mU) per
milligram of total protein, measured according to Lowry [34].
3.4.7. Carrageenan-induced paw-edema.
Rats were fasted overnight and were treated orally with indomethacin or copper-
indomethacinate-liposomes (15 mg/kg) or the vehicle. Rats were refed immediately after the
treatment. One hour later, a 0.1% solution of lambda carrageenan (kindly provided by Dr Willougby,
London, UK) (0.1 ml) was injected into the right hind foot pad. The volume of the edema was
recorded by means of plethysmography after carrageenan injection and every hour thereafter for 5
hours. Changes in paw volume relative to the measurement taken just after carrageenan
administration were calculated.
3.4.8.Statistical analysis.
The results were expressed as mean + SEM. The results were analyzed with ANOVA
procedure. If the ANOVA procedure yielded a significant interaction between variables,
comparisons between two groups were made with the Mann-Whitney U test. A statistical difference
between groups was considered significant when p<0.05.
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